# Vaccine Fact Sheet

## Tdap

| Brand Name and Manufacturer | Adacel®<sup>®</sup> | Boostrix®<sup>®</sup>  
| Sanofi Pasteur | GlaxoSmithKline (GSK) |

| Protects Against | Tetanus, diphtheria, and pertussis | Tetanus, diphtheria, and pertussis |
| Routine Schedule | One (1) booster dose: 11-12 years | One (1) booster dose: 11-12 years |
| Minimum Intervals | No minimum interval since prior Td | No minimum interval since prior Td |
| Approved for use in | Persons aged 10 through 64 years | Persons aged 10 years and older |

### Administration

| Packaging | Vaccine is packaged as 10 single-dose 0.5mL vials or 5 single-dose 0.5mL prefilled Luer-Lok syringes | Vaccine is packaged as 10 single-dose 0.5mL vials or 10 single-dose 0.5mL prefilled syringes without needles |
| Storage | Refrigerate between 36°F and 46°F (2°C to 8°C)  
**DO NOT FREEZE** | Refrigerate between 36°F and 46°F (2°C to 8°C)  
**DO NOT FREEZE** |

### Full ACIP Recommendations

- [ACIP Recommendations in Pregnant Women](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6001a4.htm?s_cid=mm6001a4_w)
- [ACIP Recommendations in Pregnant Women](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm)

### VFC Letter

| Not available on EZIZ | Not available on EZIZ |

### Billing Codes

| CHDP code: 72  
| CPT code for vaccine: 90715  
| CPT code for administration: 90460 or 90461  
| Medi-Cal Fee-For-Service (FFS) administration: 90715 with modifiers –SK (high-risk) and –SL (VFC)  
| ICD-10-CM code (encounter for immunization): Z23  
| CPT code for vaccine: 90715  
| CPT code for administration: 90460 or 90461  
| Medi-Cal Fee-For-Service (FFS) administration: 90715 with modifiers –SK (high-risk) and –SL (VFC)  
| ICD-10-CM code (encounter for immunization): Z23  

### Comments

- Licensed in 2005
- ACIP recommends 1 dose of Tdap for children ages 7 through 10 years who are not fully vaccinated against pertussis.
- 1 dose of Tdap is recommended for those ages 11 through 18 years with preferred administration at 11 through 12 years.
- Any adult 19 years of age and older who has not received Tdap should get one as soon as feasible. This dose can replace one of the 10-year Td booster doses.
- Persons who anticipate close contact with infants should receive Tdap if they haven’t previously received it, ideally at least 2 weeks before contact with the infant.
- Pregnant women should get a dose of Tdap during each pregnancy, preferably at 27 through 36 weeks gestation, irrespective of receiving Tdap in the past.
- A single dose of Tdap is recommended for healthcare personnel who have not previously received Tdap as an adult and who have direct patient contact.
- Tdap can be administered regardless of interval since the previous Td dose.

- Licensed in 2005
- ACIP recommends 1 dose of Tdap for children ages 7 through 10 years who are not fully vaccinated against pertussis.
- 1 dose of Tdap is recommended for those ages 11 through 18 years with preferred administration at 11 through 12 years.
- Any adult 19 years of age and older who has not received Tdap should get one as soon as feasible. This dose can replace one of the 10-year Td booster doses.
- Boostrix should be used for adults 65 years and older.
- Persons who anticipate close contact with infants should receive Tdap if they haven’t previously received it, ideally at least 2 weeks before contact with the infant.
- Pregnant women should get a dose of Tdap during each pregnancy, preferably at 27 through 36 weeks gestation, irrespective of receiving Tdap in the past.
- A single dose of Tdap is recommended for healthcare personnel who have not previously received Tdap as an adult and who have direct patient contact.
- Tdap can be administered regardless of interval since the previous Td dose.